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 COPD is an important and increasing cause of morbidity and mortality worldwide. COPD is pro-
jected to rank third among all causes of death by 
2020, 1 yet its impact is underestimated by health 
and government offi cials. The term “COPD” has little 
public recognition, and a clear connection has not 
been made to most of its diverse risk factors. 
 Although cigarette smoke is widely acknowledged 
as the single most important risk factor for COPD, it 
is now recognized that never smokers may account 
for between one-fourth and one-third of all COPD 
cases. 2-5 A recent review of existing data supports the 
notion that the burden of nonsmoking COPD is much 
higher than supposed in both developing and devel-
oped countries. 6 
 In the Obstructive Lung Disease in North Sweden 
(OLIN) study, Lundback et al 7 found that smokers 
accounted for only 45% of COPD cases among adults 
aged 46-77 years. Thus, other causative factors must 
be responsible for the remaining COPD burden, and 
 Background :  Never smokers comprise a substantial proportion of patients with COPD. Their 
characteristics and possible risk factors in this population are not yet well defi ned. 
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based Burden of Obstructive Lung Disease (BOLD) study. Participants were aged   40 years and 
completed postbronchodilator spirometry testing plus questionnaires about respiratory symp-
toms, health status, and exposure to COPD risk factors. A diagnosis of COPD was based on the 
postbronchodilator FEV 1 /FVC ratio, according to current GOLD (Global Initiative for Obstructive 
Lung Disease) guidelines. In addition to this, the lower limit of normal (LLN) was evaluated as an 
alternative threshold for the FEV 1 /FVC ratio. 
 Results:  Among 4,291 never smokers, 6.6% met criteria for mild (GOLD stage I) COPD, and 5.6% 
met criteria for moderate to very severe (GOLD stage II 1 ) COPD. Although never smokers were 
less likely to have COPD and had less severe COPD than ever smokers, never smokers nonethe-
less comprised 23.3% (240/1,031) of those classifi ed with GOLD stage II 1 COPD. This propor-
tion was similar, 20.5% (171/832), even when the LLN was used as a threshold for the FEV 1 /FVC 
ratio. Predictors of COPD in never smokers include age, education, occupational exposure, child-
hood respiratory diseases, and BMI alterations. 
 Conclusion:  This multicenter international study confi rms previous evidence that never smokers 
comprise a substantial proportion of individuals with COPD. Our data suggest that, in addition to 
increased age, a prior diagnosis of asthma and, among women, lower education levels are associ-
ated with an increased risk for COPD among never smokers.  CHEST 2011; 139(4):752–763 
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 The study recorded questionnaire data on respiratory symp-
toms, health status, and exposure to risk factors for COPD. All 
participants included in this analysis performed prebronchodila-
tor and postbronchodilator spirometry. 
 Spirometry Testing 
 Spirometry was performed according to American Thoracic 
Society (ATS) criteria 10 by trained and certifi ed technicians using 
the ndd EasyOne spirometer (ndd Medical Technologies; Zurich, 
Switzerland) with participants in a seated position. Separate mea-
surements were made before and at least 15 min after two puffs of 
salbutamol (200  m g) administered with a metered dose inhaler 
with Volumatic spacer (GlaxoSmithKline; Uxbridge, England). 
Spirometry data were sent electronically to the Pulmonary Func-
tion Quality Control Center in Salt Lake City, Utah, where each 
spirogram was reviewed and graded using ATS guidelines. 10 
 Studies were considered satisfactory if they met ATS accept-
ability and reproducibility criteria: at least three trials, with two 
acceptable and reproducible tests for both the FEV 1 and FVC. 
Acceptable trials were defi ned as those free from artifact, sudden 
stops, and back-extrapolated volumes greater than 5.0% of FVC. 
Trials were considered reproducible if the difference between the 
largest and second-largest values was  , 200 mL. Study techni-
cians were continuously monitored. If a technician’s quality score 
dropped below a preset level, he/she had to stop testing and be 
retrained and recertifi ed. 
 Questionnaire Data 
 Questionnaire data were obtained by face-to-face interviews 
conducted by trained and certifi ed staff in the participant’s native 
language. The questionnaire was translated from English into the 
study-site language and then back-translated to assure accuracy. 
A core questionnaire, based on standardized instruments, 9 was 
completed for all participants and included information on respi-
ratory symptoms, risk factors for COPD, health status, comor-
bidities, respiratory diagnoses, and limitation of activity. Data on 
education were used as surrogates for socioeconomic status. 
 Defi nitions 
 We defi ned irreversible airway obstruction as a postbron-
chodilator FEV 1 /FVC  , 0.7 in accordance with the GOLD 
(Global Initiative for Obstructive Lung Disease) guidelines and 
used FEV 1 to further stage the disease: FEV 1  , 80% predicted 
served as the threshold for GOLD stage II COPD, and an 
FEV 1  , 50% predicted served as the threshold for GOLD 
stage III or higher. We used the NHANES (National Health and 
Nutrition Examination Survey) III reference equations for white 
men and women to calculate predicted values. 11 Following the 
traditional practice of considering irreversible airway obstruction 
to be COPD, the COPD diagnosis was strictly based on the post-
bronchodilator lung function criteria without requiring docu-
mented exposure to a known causative agent. Unobstructed airways 
were defi ned as a postbronchodilator FEV 1 /FVC ratio   0.7. 12 
 In addition, the lower limit of normal (LLN) threshold was 
evaluated as an alternative to the fi xed ratio threshold for defi ning 
COPD. The LLN is defi ned as the lower fi fth percentile for pre-
dicted FEV 1 /FVC (ie, predicted FEV 1 /FVC  2 1.645  3 SD) based 
on the NHANES III reference equations. 11 We further defi ned 
doctor-diagnosed chronic obstructive airway disease as a self-
reported physician’s diagnosis of chronic bronchitis, emphysema, 
or COPD. 
 An ever smoker (current or former) was defi ned as a person 
who had smoked  . 20 packs of cigarettes in a lifetime or 
 . 1 cigarette/d for a year. Exposure to passive cigarette smoke 
identifi cation of these factors will be helpful for 
understanding the disease in never smokers. We 
analyzed data from 14 countries from the interna-
tional Burden of Obstructive Lung Disease (BOLD) 
study 8 to describe characteristics of COPD in never 
smokers and to identify possible risk factors in this 
population. 
 Materials and Methods 
 Study Design and Participants 
 The design and rationale for the BOLD initiative and prelimi-
nary prevalence data have been published. 8,9 Population-based sam-
pling plans were used for the recruitment of participants for all study 
sites. As of April 2008, 14 sites had completed data collection and 
are included in this analysis: Guangzhou (China), Adana (Turkey), 
Salzburg (Austria), Cape Town (South Africa), Reykjavik (Iceland), 
Hannover (Germany), Krakow (Poland), Bergen (Norway), 
Vancouver, British Columbia (Canada), Lexington, Kentucky 
(United States), Manila (Philippines), Sydney, New South Wales 
(Australia), London (England), and Uppsala (Sweden). Sampling 
designs and participant response and cooperation rates for each 
site have previously been described. 8 
 Each participating site aimed to recruit a population-based 
sample of at least 600 adults (300 men and 300 women) who were 
not institutionalized, were aged   40 years, and were living in a 
well defi ned administrative area in which the total population 
exceeded 150,000. Approval was obtained from each local ethics 
committee, and written informed consent was obtained from each 
participant. 
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 Results 
 A total of 10,000 subjects completed question-
naires, had acceptable postbronchodilator spirometry 
data, and had information on smoking status. Of this 
group, 4,291 (42.9%) were never smokers. Women 
made up 65.9% of never smokers and 42.2% of ever 
smokers. Among 5,709 ever smokers, 2,497 (43.7%) 
were current and 3,212 (56.3%) were former smokers. 
Characteristics of the study population are summa-
rized in  Table 1 . 
 Overall among never smokers, 12.2% (523/4,291) 
fulfi lled the criteria for GOLD stage I or higher, 
6.6% (283/4,291) met the criteria for mild COPD 
(GOLD stage I), and 5.6% (240/4,291) met the cri-
teria for moderate to very severe disease (GOLD 
stage II 1 ). Never smokers made up 27.7% (523/1,889) 
of all COPD cases: 33.0% (283/858) of all GOLD 
stage I cases and 23.3% (240/1,031) of all GOLD 
stage II 1 cases. Prevalence of GOLD stage II 1 
COPD (FEV 1 /FVC  , 0.7 and FEV 1  , 80% predicted) 
in never smokers (n  5 4,291) by site, sex, and age 
group is shown in  Table 2 . 
 When the LLN was used as a threshold for the 
FEV 1 /FVC ratio instead of the fi xed ratio of 0.7, 
prevalence of COPD was lower in both never 
smokers and ever smokers. The prevalence of mod-
erate to very severe airways obstruction (GOLD 
stage II 1 ) decreased by 29% (5.6% vs 4.0%) in never 
smokers and by 17% (13.9% vs 11.6%) in ever smok-
ers. When the LLN was used to defi ne airways 
obstruction, the proportion of never smokers among 
all COPD cases (FEV 1 /FVC  , LLN) and among mod-
erate to severe COPD cases (FEV 1 /FVC  , LLN and 
FEV 1  , 80% predicted) were 23.6% (302/1,282) and 
20.5% (171/832), respectively. 
 Among those with moderate to very severe airway 
obstruction (ie, GOLD stage II 1 ), never smokers 
were signifi cantly older than smokers (66.1 years 
vs 62.7 years,  P  , .001; data not shown) and were 
more likely to be women (70.8% vs 37.0%,  P  , .001; 
data not shown). The prevalence of reported doctor-
diagnosed chronic airway disease was far lower than 
that determined by spirometry in both smokers and 
never smokers. Only 18.8% of never smokers with 
moderate to severe irreversible airway obstruction 
reported a previous physician’s diagnosis of COPD, 
emphysema, or chronic bronchitis, compared with 
26.0% of ever smokers. Thus, 81.2% of never smok-
ers with mod erate to severe airway obstruction were 
undiagnosed. 
 COPD Prevalence by Age and Sex 
 Prevalences of GOLD stage II and GOLD 
stage III 1 by age, sex, and smoking status are 
shown in  Figure 1 . As expected, the prevalence of 
was defi ned as an affi rmative answer to whether anyone (other 
than the participant) had smoked a cigarette, pipe, or cigar in the 
participant’s home during the past 2 weeks. 
 To assess occupational exposure, participants were asked 
whether they had worked   3 months in occupations known or 
suspected to be associated with the risk of COPD and, if so, the 
number of years spent in each occupation. Occupational expo-
sures were grouped into three categories: (1) organic dust (through 
farming; fl our-, feed-, or grain-milling; cotton- or jute-processing; 
forestry- or wood-milling; and fi sh-processing); (2) inorganic dust 
(through asbestos; aluminum, coal, or hard-rock mining; tunneling, 
foundry, or steel-milling; and sandblasting); (3) irritant gases, fumes, 
or vapors (through welding, fi re fi ghting, chemical or plastic man-
ufacturing, public transportation, and dry-cleaning chemicals). 
 Four measures of biomass exposure were based on self-reported 
responses indicating whether participants had experienced at 
least 6 months’ use of indoor fi re for (1) cooking using coal or 
coke; (2) cooking using wood, crop residues, or dung; (3) heating 
using coal or coke; and (4) heating using wood, crop residues, or 
dung. Participants also reported the number of years of exposure 
for each category. 
 Additional measures evaluated included BMI (kg/m 2 ); total 
number of years of education; self-reported hospitalization for 
breathing problems prior to the age of 10 years; self-reported 
respiratory symptoms for cough, phlegm, wheezing, and dyspnea; 
and self-reported physician-diagnosed asthma, COPD, chronic 
bronchitis, emphysema, TB, heart disease, hypertension, diabe-
tes, or stroke. 
 Health status measures included two indicators of participants 
who (1) responded “excellent” or “very good”  (vs “good,” “fair,” or 
“poor”) when asked to rate their general health, and (2) responded 
“none of the time” or “a little of the time” (vs “some,” “most,” or “all” 
of the time) when asked how much of the time they experienced limi-
tations in work or other activities “as a result of your physical health.” 
 Statistical Analysis 
 Our analysis includes BOLD participants who completed the 
primary study questionnaire and had acceptable postbronchodila-
tor spirometry measures. Bivariate comparisons were performed 
using the Wilcoxon rank sum test to compare continuous mea-
sures across groups and  x 2 tests to compare categorical measures. 
Logistic regression models were fi tted separately for never smoker 
men and women to evaluate associations with GOLD stage II or 
higher relative to (ie, FEV 1 /FVC   0.7) never smokers with unob-
structed airways. Covariates included in the model were specifi ed 
a priori. Because of the uncertain clinical relevance of GOLD stage I 
COPD, data for this group are presented separately from those 
for GOLD stages II 1 (moderate to very severe airway obstruc-
tion), and most analyses focus on comparing the latter group to 
the unobstructed-airways group. Models included age category 
(40-49, 50-59, 60-69, 70-79, and 80 1 years); years of school; 
BMI category ( , 18.5, 18.5-24.9, 25-29.9, 30-34.9,   35 kg/m 2 ); 
passive-smoking exposure (yes/no [y/n]); hospitalization for 
breathing problems as a child (y/n); self-reported physician-
diagnosed conditions (y/n) including asthma, TB, cardiovascular 
disease, or diabetes; and indicators (y/n) for   10 years of expo-
sure to cooking biomass, heating biomass, occupational organic 
dusts, occupational inorganic dusts, and occupational gases, vapors, 
or fumes. The model specifi ed robust variance estimators for clus-
tered data to account for correlation of observations within site 
(or of groups within site, as defi ned by the site sampling plan). 13 
Estimated ORs, 95% CIs, and  P values are reported. A  P value 
of 0.05 was considered statistically signifi cant. No adjustments 
for multiple comparisons were made. Analyses were performed 
using SAS, version 9 (SAS Institute Inc; Cary, North Carolina) 
and Stata, version 9.2 (Stata Corp, College Station, Texas). 
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 Clinical Profi le of COPD in Never Smokers 
 Never smokers with moderate to severe airway 
obstruction tended to be older, had less education, 
and reported roughly double the frequency of 
respiratory symptoms (cough, phlegm, wheeze, dysp-
nea) compared with never smokers with unob-
structed airways. The former group also had higher 
frequencies of self-reported physician-diagnosed 
asthma, heart disease, TB, and hypertension and 
were more likely to have been hospitalized for 
breathing problems as a child and to have left a job 
due to breathing problems ( Table 3 ). In addition, 
never smokers with mod erate to severe airway obstruc-
tion reported more frequent exposure to indoor open 
moderate to severe COPD increased with age in 
both ever and never smokers ( P  , .001). Among ever 
smokers, COPD prevalence was generally higher in 
men than women (17.1% vs 13.2%,  P  , .001); however, 
among never smokers the distributions of COPD 
by age were similar between men and women (5.2% 
vs 6.2%,  P  5 .142). 
 Among those with COPD GOLD stage II 1 COPD, 
the proportion of moderate airway obstruction 
(GOLD stage II) was similar in never smokers and 
ever smokers (40.0% vs 43.8%,  P  5 .134). However, 
severe (GOLD stage III) and very severe (GOLD 
stage IV) airway obstruction was signifi cantly lower 
in never smokers (5.9% vs 14.1%,  P  , .001) ( Fig 1 ). 
 Table 1— Population Characteristics for Never Smokers and Ever Smokers 
Characteristic Never Smokers (n  5 4,291) Ever Smokers (n  5 5,709)
Men, No. (%) 1,464 (34.1) 3,302 (57.8)
 Age, mean (SE), y 56.2 (11.7) 56.3 (11.2)
 Age category, a No. (%)
  40-49 536 (36.6) 1,100 (33.3)
  50-59 387 (26.4) 1,004 (30.4)
  60-69 322 (22.0) 709 (21.5)
  70-79 170 (11.6) 399 (12.1)
  80 1 49 (3.4) 90 (2.7)
 BMI, mean (SE) b kg/m 2 27.3 (4.3) 26.7 (4.6)
 Education, mean (SE), b y 12.2 (4.4) 10.6 (4.1)
 Smoking,  . 20 pack-years … 1,764 (53.5)
 Lung function b 
  FEV 1 , mean (SD) 3.46 (0.81) 3.09 (0.87)
  FVC, mean (SD) 4.47 (0.97) 4.17 (1.0)
  FEV 1 /FVC, mean (SD) 77.38 (6.78) 73.72 (10.06)
  FEV 1 /FVC   0.7 1,273 (87.0) 2,421 (73.3)
  FEV 1 /FVC  , 0.7 and FEV 1   80% predicted (GOLD stage I) 121 (8.3) 383 (11.6)
  FEV 1 /FVC  , 0.7 and FEV 1  , 80% predicted (GOLD stage II 1 ) 70 (4.8) 498 (15.1)
  FEV 1 /FVC  , LLN (NHANES fi fth percentile) 87 (5.9) 557 (16.9)
  FEV 1 /FVC  , LLN (NHANES fi fth percentile) and FEV 1  , 80% predicted 41 (2.8) 393 (11.9)
Women, No. (%) 2,827 (65.9) 2,404 (42.2)
 Age, mean (SE), b y 57.6 (12.0) 55.3 (11.0)
 Age category, No. (%) b 
  40-49 876 (31.0) 868 (36.1)
  50-59 805 (28.5) 772 (32.1)
  60-69 653 (23.1) 488 (20.3)
  70-79 366 (13.0) 199 (8.3)
  80 1 127 (4.5) 80 (3.2)
 BMI, mean (SE) a kg/m 2 27.5 (5.9) 27.2 (6.1)
 Education, mean (SE), b y 10.3 (7.3) 11.0 (5.2)
 Smoking,  . 20 pack-years … 889 (36.9)
 Lung function b 
  FEV 1 , mean (SD) 2.27 (0.61) 2.36 (0.65)
  FVC, mean (SD) 2.90 (0.73) 3.11 (0.76)
  FEV 1 /FVC, mean (SD) 78.30 (7.35) 75.50 (9.52)
  FEV 1 /FVC   0.7 2,495 (88.3) 1,922 (79.9)
  FEV 1 /FVC  , 0.7 and FEV 1   80% predicted (GOLD stage I) 162 (5.7) 192 (8.0)
  FEV 1 /FVC  , 0.7 and FEV 1  , 80% predicted (GOLD stage II 1 ) 170 (6.0) 293 (12.2)
  FEV 1 /FVC  , LLN (NHANES fi fth percentile) 215 (7.6) 423 (17.6)
  FEV 1 /FVC  , LLN (NHANES fi fth percentile) and FEV 1  , 80% predicted 130 (4.6) 267 (11.1)
 GOLD  5 Global Initiative for Chronic Obstructive Lung Disease; GOLD stage II 1  5 GOLD stages II, III, and IV; LLN  5 lower limit of normal; 
NHANES  5 National Health and Nutrition Examination Survey. 
 a .001    P  , 0.05 for  x 2 test (for categorical data) or Wilcoxon rank sum test (for continuous data), comparing never smokers to ever smokers. 
 b P  , 0.001 for  x 2 test (for categorical data) or Wilcoxon rank sum test (for continuous data), comparing never smokers to ever smokers. 
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GOLD stage II 1 ) and were used in logistic regression 
models. Among men and women never smokers, our 
analyses showed a strong association between increas-
ing age and increasing odds of GOLD stage II 1 
COPD ( Table 4 ). A strong association was also noted 
in both men and women for self-reported, physician-
diagnosed asthma. 
 OR estimates for hospitalization related to breath-
ing problems as a child were fairly similar in men and 
women (2.82 and 2.21, respectively); however, neither 
quite reached statistical signifi cance. The OR estimates 
for exposure to organic dust were also similar for men 
(OR  5 2.18,  P  5 .054) and women (OR  5 1.96,  P  5 .007) 
but reached statistical signifi cance only in women. 
fi re with coal or coke for cooking (26.9% vs 19.7%), 
with 22.0% vs 15.3% reporting at least 10 years of 
exposure, and exposure to organic dusts in the work-
place (30.4% vs 23.0%), with 19.3% vs 10.1% reporting 
at least 10 years of exposure ( P  , .05, all measures) 
( Table 2 ). The clinical profi le of never smokers with 
mild airway obstruction (GOLD stage I) was gener-
ally similar to the profi le of unaffected never smokers 
( Table 3 ). 
 Factors Associated With COPD in Never Smokers 
 Complete data were available on 2,578 women 
(159 with GOLD stage II 1 ) and 1,311 men (67 with 
 Table 2— Prevalence of GOLD Stage II 1 COPD (FEV 1 /FVC  , 0.7 and FEV 1  , 80% Predicted) in Never Smokers 
(n  5 4,291) by Site, Sex, and Age Group 
Site (Country) Sex 40-49 y 50-59 y 60-69 y 70-79 y 80 1 y All
Guangzhou (China) Female 2.1 1.6 7.8 15.4 … 4.0
Male 0.0 0.0 16.7 0.0 50.0 4.6
All 1.8 1.3 8.8 10.0 50.0 4.1
Adana (Turkey) Female 1.9 3.5 14.5 10.3 0.0 5.9
Male 0.0 5.0 9.1 9.1 0.0 5.3
All 1.6 3.8 13.1 10.0 0.0 5.8
Salzburg (Austria) Female 2.7 4.7 2.9 17.5 27.8 6.6
Male 0.0 4.4 5.3 14.3 0.0 4.4
All 1.3 4.5 3.9 16.0 17.2 5.6
Cape Town (South Africa) Female 1.2 6.5 14.0 23.1 20.0 8.5
Male 4.2 0.0 0.0 0.0 … 2.0
All 1.9 5.4 11.5 20.0 20.0 7.3
Reykjavik (Iceland) Female 0.0 0.0 15.4 11.5 36.4 7.9
Male 0.0 0.0 12.1 20.0 16.7 5.2
All 0.0 0.0 13.6 14.6 29.4 6.4
Hannover (Germany) Female 0.0 2.5 2.0 5.3 12.5 3.0
Male 0.0 13.6 2.4 7.1 … 4.7
All 0.0 6.5 2.2 5.8 12.5 3.7
Krakow (Poland) Female 2.8 5.9 16.3 15.4 25.0 10.9
Male 0.0 10.0 0.0 0.0 50.0 3.6
All 1.5 6.8 14.0 12.9 30.0 8.9
Bergen (Norway) Female 0.0 0.0 2.9 0.0 22.7 4.3
Male 6.3 3.7 8.0 11.1 18.2 7.7
All 3.7 1.7 5.1 2.6 21.2 5.7
Vancouver, British Columbia (Canada) Female 2.4 1.2 7.7 6.5 0.0 3.2
Male 0.0 5.9 11.8 8.3 0.0 4.1
All 1.4 2.9 8.9 7.0 0.0 3.5
Lexington, Kentucky (United States) Female 0.0 0.0 12.1 18.8 0.0 5.0
Male 0.0 0.0 0.0 0.0 0.0 0.0
All 0.0 0.0 8.9 12.5 0.0 3.5
Manila (Philippines) Female 3.3 4.1 12.5 20.0 36.4 7.0
Male 8.1 6.3 0.0 33.3 50.0 9.5
All 4.3 4.4 11.5 21.7 38.5 7.4
Sydney, New South Wales (Australia) Female 7.1 7.5 14.8 16.1 0.0 10.1
Male 2.6 3.3 0.0 4.6 50.0 4.2
All 4.9 5.7 8.0 11.3 16.7 7.5
London (England) Female 2.5 0.0 4.1 9.5 33.3 5.2
Male 2.4 0.0 8.0 30.0 0.0 5.7
All 2.5 0.0 5.4 16.1 23.1 5.4
Uppsala (Sweden) Female 0.0 2.8 0.0 5.3 33.3 2.4
Male 2.9 3.2 0.0 20.0 0.0 4.7
All 1.5 3.0 0.0 11.8 14.3 3.4
Values are presented as %. See Table 1 for expansion of abbreviation.
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Town (OR  5 4.63,  P  5 .005), Salzburg (OR  5 2.75, 
 P  5 .057), Krakow (OR  5 5.70,  P  5 .010), Sydney, 
Australia (OR  5 4.50,  P  5 .010) and Manila (OR  5 3.85, 
 P  5 .010). When location was included in the model 
for men, the association of GOLD stage II 1 with 
childhood hospitalization for breathing problems was 
strengthened (OR  5 4.55,  P  5 .005), as were associa-
tions for those with BMI between 30 and 35 kg/m 2 
(OR  5 2.72,  P  5 .037) and BMI  . 35 kg/m 2 (OR  5 5.28, 
 P  5 .004) compared with those in the normal range. 
The largest estimated site OR, relative to Hannover, 
was for Manila (OR  5 3.27,  P  5 .061). 
 Results of these multivariate analyses did not 
change markedly for most measures when LLN was 
used as a threshold for the FEV 1 /FVC ratio instead 
of the fi xed ratio ( Table 5 ). However, a clear dif-
ference was seen in the age association in women. 
OR estimates for the three age groups 60 1 years were 
smaller in the LLN regression and only remained statis-
tically signifi cant for the oldest age group (80 1 years). 
The OR estimates for organic dust increased from 
1.96 ( P  5 .007) to 2.60 ( P  , .001) in women but were 
not changed markedly in men. The effect seen for child-
hood hospitalization was slightly stronger in women 
in the LLN model (OR 2.21,  P  5 .087 vs OR 2.42, 
 P  5 .043) and substantially weaker in men (OR 2.82, 
 P  5 .065 vs OR 1.30,  P  5 .711). The prevalence of the 
latter two measures were low; hence substantial fl uc-
tuations in their OR estimates are coherent. 
 Discussion 
 There were three main fi ndings in this study: 
(1) This multicenter, international study confi rms pre-
vious evidence that never smokers are a substantial 
proportion of individuals with COPD and that they 
are usually not diagnosed with the disease. (2) More 
than two-thirds of never smokers with moderate to 
severe airway obstruction are women. (3) Predictors 
of COPD in never smokers include age, education, 
occupational exposure, childhood respiratory dis-
eases, and BMI alterations. 
 This analysis of trial-wide BOLD data shows that 
28% of irreversible airways obstruction—about 33% 
of mild airway obstruction (GOLD stage I) and about 
23% of moderate to very severe airway obstruction 
(GOLD stage II 1 )—occurs in never smokers aged 
40 to 98 years. This fi nding is consistent with an anal-
ysis of (prebronchodilator) NHANES III data in 
US adults (aged 18 to 80 years), which showed that 
about one-fourth of COPD cases occurred in sub-
jects with no smoking history. 3 A study in an older 
population in China has shown that 38.6% of sub-
jects with COPD had never smoked. 14 COPD does 
not develop suddenly, but rather exposure to risk 
 Among women, each additional year of education 
decreased odds of GOLD stage II 1 COPD by about 
6% (OR  5 0.94,  P  5 .005), and the OR for exposure 
to passive smoking was 1.53, which did not reach 
statistical signifi cance ( P  5 .064). In men, the ORs for 
both these measures were close to 1.00 ( P  . .69). 
Among both men and women, BMI  , 20 kg/m 2 was 
associated with increased odds of GOLD stage II 1 
compared with those in the normal range (20-25 kg/m 2 ), 
and the OR estimate for men was about fi ve times 
that for women (13.39 vs 2.56). 
 When these models were adjusted for location, 
the results were generally similar, although among 
women the relationship of passive smoking with 
GOLD stage II 1 was attenuated (OR  5 1.28,  P  5 .292), 
whereas the associations for the two highest BMI 
categories were strengthened (OR  5 0.56,  P  5 .044 
for BMI 30-35 kg/m 2 and OR  5 0.51,  P  5 .051 for 
BMI  . 35 kg/m 2 ). Compared with the Hannover 
site (the site with the lowest overall prevalence of 
GOLD stage II 1 among those studied), never-smoker 
women from the following sites were most likely to 
experience increased risk for GOLD stage II 1 : Cape 
 Figure 1. Prevalence of GOLD stage II 1 COPD among partici-
pants by smoking status, sex, and age (y). GOLD  5 Global Initia-
tive for Obstructive Lung Disease; GOLD stage II 1  5 GOLD 
stages II, III, and IV. 
758 Original Research
this susceptibility may also apply to other harmful 
exposures. Moreover, the presence of chronic air-
way obstruction in never smokers raises the question 
of whether there is an autoimmune component to 
COPD pathogenesis. 19,20 As most autoimmune dis-
eases occur more frequently in women than men, 
the autoimmune hypothesis is worth considering 
as a contributor to the predominance of females 
among never smokers with COPD. 
 In our study population, 81.2% of never smokers 
with moderate to severe airway obstruction were 
factors over a considerable period of time. Thus, 
prevalence of COPD increases with age in both smok-
ers and never smokers. 12 
 In our sample, more than two-thirds of never 
smokers with moderate to severe airway obstruction 
were women. These results agree with results from a 
population-based study in Spain 15 and recently pub-
lished results from the Swiss Study on Air Pollution 
and Lung Disease in Adults (SAPALDIA) cohort 
study. 5 Studies have suggested that women are more 
susceptible to the effects of tobacco smoke, 16-18 and 
 Table 3— Characteristics, Respiratory Symptoms, Physician Diagnoses, and Risk Factors for Airway Obstruction 
Among Never Smokers (n  5 4,291) 
Variable FEV 1 /FVC   0.7 GOLD stage I GOLD stage II 1 
Subjects, No. 3,768 283 240
Age, mean (SE), y 55.7 (11.1) 66.7 (12.5) 66.1 (12.0) a 
Women 2,495 (66.2) 162 (57.2) 170 (70.8)
Education  , 12 y 966 (25.6) 77 (27.2) 91 (37.9) a 
BMI, kg/m 2 , mean (SE) 27.6 (5.5) 27.1 (4.2) 27.4 (6.0)
Respiratory symptoms
 Cough 650 (17.3) 67 (23.7) 78 (32.5) a 
 Phlegm 631 (16.8) 55 (19.4) 82 (34.2) a 
 Wheezing 571 (15.2) 64 (22.6) 91 (37.9) a 
 Dyspnea on exertion 823 (21.8) 58 (20.5) 97 (40.4) a 
 Any of the above symptoms 1,675 (44.5) 140 (49.5) 174 (72.5) a 
Physician diagnosis, ever
 Asthma 371 (9.9) 50 (17.7) 73 (30.4) a 
 COPD 18 (0.5) 1 (0.4) 9 (3.8) a 
 Chronic bronchitis 105 (2.8) 14 (5.0) 33 (13.8) a 
 Emphysema 27 (0.7) 10 (3.5) 15 (6.3) a 
 Any of the above diagnoses 451 (12.0) 63 (22.3) 98 (40.8) a 
 TB 108 (2.9) 11 (3.9) 17 (7.1) a 
 Heart disease 422 (11.2) 60 (21.2) 51 (21.3) a 
 Hypertension 1,198 (31.8) 108 (38.2) 119 (49.6) a 
 Diabetes 283 (7.5) 18 (6.4) 24 (10.0)
 Stroke 89 (2.4) 13 (4.6) 7 (2.9)
Hospitalized for breathing problems prior to the age of 10 y 111 (3.0) 5 (1.8) 15 (6.3) b 
Worked in any dusty job  . 1 y 1,180 (31.3) 87 (30.7) 76 (31.7)
Ever had to leave a job due to breathing problems 83 (2.2) 5 (1.8) 13 (5.5) b 
Exposure to
 Passive smoking at home 792 (21.0) 47 (16.6) 53 (22.1)
 Indoor open fi re with coal/coke for cooking c 566 (19.7) 41 (20.4) 50 (26.9) b 
   10 y exposure, cooking with coal/coke 439 (15.3) 31 (15.4) 41 (22.0) b 
 Indoor open fi re with coal/coke for heating c 532 (18.5) 51 (25.4) 39 (21.0)
   10 y exposure, heating with coal/coke 327 (11.4) 40 (19.9) 27 (14.5)
 Indoor open fi re with wood/crop/dung for cooking c 818 (28.4) 42 (20.9) 57 (30.7)
   10 y exposure, cooking with wood/crop/dung 564 (19.6) 28 (13.9) 43 (23.1)
 Indoor open fi re with wood/crop/dung for heating c 563 (19.6) 37 (18.4) 38 (20.4)
   10 y exposure, heating with wood/crop/dung 436 (15.1) 32 (15.9) 30 (16.1)
 Biologic/organic dusts at the workplace 867 (23.0) 80 (28.3) 73 (30.4) b 
   10 y exposure, biologic/organic dusts 378 (10.1) 39 (13.8) 46 (19.3) a 
 Inorganic dusts at the workplace 217 (5.8) 28 (9.9) 11 (4.6)
   10 y exposure, inorganic dusts 62 (1.7) 11 (3.9) 3 (1.3)
 Irritant gases, fumes, or vapors at the workplace 326 (8.7) 25 (8.8) 15 (6.3)
   10 1 y exposure, gases, fumes or vapors 141 (3.8) 10 (3.6) 12 (5.0)
Values presented as No. (%) unless otherwise noted.
 a P  , .001 for  x 2 test (for categorical data) or Wilcoxon rank sum test (for continuous data) comparing the unobstructed-airways group 
(FEV 1 /FVC   0.7) with the GOLD stage II 1 group.
 b .001    P  , 0.05 for  x 2 test comparing the unobstructed-airways group (FEV 1 /FVC   0.7) with the COPD II 1 group.
 c Three sites, Hannover (Germany), Uppsala (Sweden), and Bergen (Norway), did not collect information on biomass exposures, thus n  5 2,879, 201, 
and 186 for the FEV 1 /FVC   0.7, GOLD stage I, and GOLD stage II 1 groups, respectively.
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mechanisms. 24,25 Grain dust, for example, can cause 
recruitment of neutrophils to the proximal and dis-
tal airways. 26,27 The results of our study suggest an 
increased risk of COPD in women after occupational 
exposure to organic dusts for   10 years. Similar 
effects were not seen for inorganic dusts and gases, 
vapors, and fumes; however, the numbers of partici-
pants with these exposures was relatively small in 
this never-smoker population. 
 Biomass fuels used by women for cooking and 
heating have been shown to cause COPD in non-
smoking women. 28-32 In our data, exposure to indoor 
open fi re (with coal or coke) for cooking was bivari-
ately associated with COPD in never smokers, for 
whom clinical characteristics, impairment in quality 
of life, and increase in mortality are similar to tobacco 
smokers. 33 However, we did not fi nd statistically sig-
nifi cant associations of at least 10 years of reported 
exposure to heating or cooking biomass in the logistic 
regressions. 
 There is evidence that exposure to environmental 
tobacco smoke is associated with COPD 34-36 and affects 
women more often than men. 37,38 In our study, we 
previously undiagnosed. This clearly refl ects the lack 
of recognition and underdiagnosis of obstructive lung 
disease among never smokers, possibly as a result of 
little knowledge on this condition and poor under-
standing and appreciation of risk factors other than 
smoking. 
 Risk Factors for COPD in Never Smokers 
 There is evidence that a substantial proportion 
of COPD, up to 20%, can be attributed to occupa-
tional exposures. 21 The ATS concluded that occu-
pational exposures account for 10% to 20% of both 
symptoms and functional impairment consistent with 
COPD. 22 In an analysis of NHANES III data, the 
fraction of COPD in never smokers that is attribut-
able to work has been estimated to be 31%. 23 In our 
data, never smokers with moderate to severe COPD 
reported exposure to organic dusts in the workplace 
more often than did never smokers with unobstructed 
airways (30.4% vs 23%). There is some evidence 
that the airway response to organic dust inhalation 
is primarily mediated by nonallergic infl ammatory 
 Table 4— Independent Predictors of GOLD Stage II 1 COPD in Never Smokers: Multivariate Logistic Model 
Variable
Women ( n  5 2,578) Men (n  5 1,311)
OR  P Value 95% CI OR  P Value 95% CI
Age, y
 40-49 Reference Reference
 50-59 1.37 .311 0.75-2.52 2.71 .023 1.14-6.38
 60-69 4.31  , .001 2.50-7.44 4.88  , .001 2.03-11.70
 70-79 6.15  , .001 3.31-11.44 10.85  , .001 4.32-27.22
 80 1 12.97  , .001 6.56-25.65 29.02  , .001 8.56-98.39
Education, y
 1-y increase 0.94 .005 0.90-0.98 0.99 .700 0.93-1.05
  10 y exposure in high-risk occupation
 Organic dust 1.96 .007 1.20-3.20 2.18 .054 0.99-4.80
 Inorganic dust a … … … 0.72 .617 0.19-2.65
 Gases/vapors 0.65 .506 0.18-2.32 1.54 .270 0.71-3.34
Biomass fuel
   10 y cooking 1.03 .899 0.67-1.57 1.39 .514 0.52-3.75
   10 y heating 0.81 .386 0.50-1.31 0.55 .255 0.20-1.53
Passive smoking
 Exposed 1.53 .064 0.98-2.41 0.97 .954 0.40-2.40
Childhood hospitalization
 Yes 2.21 .087 0.89-5.47 2.82 .065 0.94-8.51
Comorbidities, diagnosis
 HD/HT/DM 1.13 .499 0.79-1.63 1.28 .433 0.69-2.36
 Asthma 4.62  , .001 3.04-7.02 4.12  , .001 2.06-8.26
 TB 1.47 .323 0.69-3.12 1.65 .464 0.43-6.34
BMI, kg/m 2 
 BMI  , 20 2.56 .002 1.40-4.71 13.39  , .001 3.67-48.84
   20 BMI  , 25 Reference Reference
   25 BMI  , 30 0.74 .182 0.48-1.15 1.28 .518 0.61-2.67
   30 BMI  , 35 0.65 .130 0.37-1.14 2.19 .066 0.95-5.05
 BMI   35 0.62 .147 0.33-1.18 3.19 .030 1.11-9.11
DM  5 diabetes mellitus; HD  5 heart disease; HT  5 hypertension.
 a This term was excluded from the model for women as there were only 11 women with the exposure, none of whom had GOLD stage II 1 COPD, 
making the OR unestimable.
760 Original Research
prevalence of reported TB was present among never 
smokers with airway obstruction than never smok-
ers without obstruction. However, it did not appear 
as a signifi cant independent predictor in the multi-
variable logistic model, possibly because of the 
widely differing prevalences of TB in the BOLD 
study sites. 
 COPD can be associated with a progressive loss of 
skeletal muscle mass; low BMI is an independent 
predictor of the risk of death. 45 In our study, increased 
odds of GOLD stage were seen in   10 men and 
women from the never-smoker population with low 
BMI ( , 20 kg/m 2 ). However, the OR estimate for men 
was about fi ve times higher than for women (13.37 
vs 2.57). In contrast, a high BMI ( . 35 kg/m 2 ) was 
associated with increased odds of GOLD stage II 1 
only in men. Overall, the association between BMI 
alterations and the presence of COPD was much 
more pronounced in men than women from the 
never-smoker group. It has been shown that a diet 
rich in meat and refi ned grains may increase the risk 
of COPD, whereas a diet with higher intakes of 
vegetables, fruits, and fi sh may reduce this risk. 46,47 
did not observe an increased risk of GOLD stage II 1 
COPD associated with exposure to passive smoking. 
However, the BOLD questionnaire only assessed 
current exposure to passive smoking at home within 
the last 2 weeks and did not consider earlier expo-
sures to passive smoking or to passive smoking in the 
workplace. 
 Low socioeconomic status, 39 low level of educa-
tion, 40 and severe childhood respiratory infections 41,42 
have been shown to be associated with a higher 
prev alence of COPD. In our analysis, more years 
of education was associated with lower odds of 
spirometrically determined COPD among female 
never smokers. Likewise, severe childhood respira-
tory infections or other breathing problems (leading 
to hospitalization) and COPD were associated in 
never smokers. 
 Pulmonary TB is a frequent cause of chronic 
pulmonary function impairment, particularly airfl ow 
obstruction, 43,44 and constitutes an important differ-
ential diagnosis to COPD in high-prevalence areas, 
especially in the absence of other typical risk factors 
for COPD. 12 Our data show that a signifi cantly higher 
 Table 5— Independent Predictors of GOLD Stage II 1 COPD (LLN) in Never Smokers (Multivariate Logistic Model) 
Variable
Women (n  5 2,578) Men (n  5 1,311)
OR  P Value 95% CI OR  P Value 95% CI
Age, y
 40-49 Reference Reference
 50-59 0.66 .151 0.38-1.16 2.63 .050 1.00-6.97
 60-69 1.60 .076 0.96-2.69 3.57 .022 1.21-10.57
 70-79 1.43 .276 0.75-2.74 11.47  , .001 3.93-33.52
 80 1 3.24 .001 1.57-6.71 4.20 .185 0.50-35.17
Education, y
 1 y increase 0.93 .004 0.89-0.98 1.03 .340 0.96-1.12
  10 y exposure in high-risk occupation
 Organic dust 2.60  , .001 1.56-4.35 2.60 .074 0.91-7.46
 Inorganic dust a … … … 0.47 .453 0.07-3.30
 Gases/vapors 0.44 .369 0.07-2.64 1.44 .501 0.50-4.16
Biomass fuel
   10 y cooking 0.81 .386 0.50-1.30 0.85 .838 0.19-3.86
   10 y heating 0.81 .448 0.48-1.39 0.41 .225 0.10-1.73
Passive smoking
 Exposed 1.04 .873 0.65-1.66 1.13 .826 0.39-3.30
Childhood hospitalization
 Yes 2.42 .043 1.03-5.74 1.30 .711 0.32-5.21
Comorbidities, diagnosis
 HD/HT/DM 1.24 .279 0.84-1.81 0.74 .478 0.32-1.69
 Asthma 4.60  , .001 3.01-7.02 5.00  , .001 2.29-10.95
 TB 1.29 .584 0.52-3.23 3.09 .177 0.60-15.95
BMI kg/m 2 
 BMI  , 20 2.06 .042 1.03-4.15 6.85 .024 1.29-36.38
   20 BMI  , 25 Reference Reference
   25 BMI  , 30 0.76 .253 0.48-1.21 1.44 .438 0.57-3.62
   30 BMI  , 35 0.51 .033 0.28-0.95 2.15 .175 0.71-6.53
 BMI   35 0.75 .356 0.41-1.38 5.71 .004 1.76-19
See Table 1 and 4 legends for expansion of abbreviations.
 a This term was excluded from the model for women as there were only 11 women with the exposure, none of whom had GOLD stage II 1 , making 
the OR unestimable.
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subject to potential survival bias; susceptible per-
sons might have terminated or decreased their 
exposure to harmful substances that caused symp-
toms before a harmful threshold of exposure was 
reached. However, in this population, we did not 
have suffi cient data to evaluate fi ner exposure inter-
vals. In addition, many of our measures are based 
on self-reporting, which can be subject to inaccurate 
recall. 
 Conclusions 
 A substantial proportion of patients with COPD 
have not had signifi cant exposures to tobacco smoke. 
Therefore, increased awareness and understanding 
of other factors that may cause this disease are 
needed. Our data suggest that, in addition to increased 
age, a prior diagnosis of asthma and, among women, 
lower education levels are associated with an increased 
risk for COPD among never smokers. Exposure to 
organic dusts in the workplace and history of severe 
childhood respiratory tract infections may also be 
important factors. Symptomatic never smokers should 
be included in clinical surveillance and screening 
efforts for COPD. 
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Given the cross-sectional nature of our data, we can-
not discriminate whether low BMI precedes COPD 
or is rather a consequence of the disease. 
 Limitations 
 Reference equations for spirometric variables are 
not available for many parts of the world. Even if 
country-specifi c or race-specifi c reference equations 
were available for all sites, their use might have draw-
backs, such as masking true differences related to expo-
sure between countries or between racial groups within 
countries. BOLD uses the widely accepted predic-
tion equations derived from the third US NHANES, 11 
which may not ideally fi t for all studied populations. 
In addition to this, “self-stated race” has been shown 
to result in more misclassifi cations of the severity of 
impairment of lung function. 48 
 The use of a fi xed threshold to defi ne airways 
obstruction is associated with some extent of misclas-
sifi cation. 49 The age- and sex-specifi c LLN can be used 
as an alternative threshold for the FEV 1 /FVC ratio. 
As summarized in a review, 6 previous studies have 
almost exclusively used the fi xed ratio to defi ne 
COPD in never smokers. However, we performed a 
sensitivity analysis to evaluate whether use of the 
LLN would have markedly changed the results of 
this study. When the LLN was used instead of the 
fi xed ratio, the proportion of never smokers among 
all cases of moderate to severe COPD was almost 
unchanged. Except for differences in the age associa-
tion in women, logistic model results were generally 
similar regarding characteristics and predictors of 
GOLD  stage II 1 COPD in never smokers when the 
LLN was used instead of the fi xed ratio. 
 The results need to be interpreted with caution 
because diagnosis of COPD and its severity are based 
on one lung function measurement (including several 
postbronchodilator maneuvers). It is known that the 
obstruction may be more severe or absent after 
another measurement. 
 The required sample size of at least 300 men 
and 300 women in every site allowed more sites 
the opportunity to participate in the study and pro-
vided adequate power for estimating COPD prev-
alence, but it limits our ability to draw conclusions 
regarding potential risk factors with low to moder-
ate prevalence, particularly in our never-smoker 
population. 
 Some analyses were limited because of the design 
of the questionnaires, which were intended to be 
comprehensive and easy to administer, but in some 
cases did not allow for optimally detailed data col-
lection (eg, for exposures to passive smoke, bio-
mass, and high-risk occupations). Furthermore, our 
analyses based on   10 years of exposure may be 
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